Moderna (MRNA) Revenue — Quarter Ended Sep 30, 2023
Revenue for the quarter increased sharply compared to the immediately preceding quarter. However, revenue declined compared to the same quarter one year earlier.
Key takeaway
Quarter ended Sep 30, 2023 · FY2023 Q3
Revenue for the quarter increased sharply compared to the immediately preceding quarter. However, revenue declined compared to the same quarter one year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.8B
Revenue reported for this quarter.
Quarter-over-quarter
+432.3%
Change from the immediately preceding quarter.
Year-over-year
-45.6%
Change from the comparable year-ago quarter.
Trailing four quarters
$9.1B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $5.1B | -29.5% |
| Mar 31, 2023 | $1.9B | -69.3% |
| Jun 30, 2023 | $344M | -92.8% |
| Sep 30, 2023 | $1.8B | -45.6% |
Revenue performance
The reported revenue direction is upward from the prior quarter, reversing a multi-quarter decline. The sequential improvement reflects a significant rebound in quarterly sales.
Quarterly comparison
Compared to the immediately preceding quarter, revenue rose substantially. Compared to the same quarter one year earlier, revenue was lower, continuing a year-over-year decline trend.
What to watch
Monitor whether the sequential revenue improvement can be sustained in future quarters.